{"contentid": 488771, "importid": NaN, "name": "Shield Therapeutics appoints new CEO", "introduction": "Specialty UK pharma company Shield Therapeutics, with a focus on addressing iron deficiency with its lead product Feraccru/Accrufer (ferric maltol), today announced that Greg Madison has been appointed as chief executive, with effect from Tuesday, June 1, 2021.", "content": "<p>Specialty UK pharma company Shield Therapeutics (LSE: STX), with a focus on addressing iron deficiency with its lead product Feraccru/Accrufer (ferric maltol), today announced that Greg Madison has been appointed as chief executive, with effect from Tuesday, June 1, 2021.&nbsp;</p>\n<p>Mr Madison is a seasoned executive who brings strong operating experience and a track record of success leading small to medium size organizations. Prior to joining Shield, he was CEO at Melt Pharmaceuticals in Boston, USA, a company developing a sublingual formulation of midazolam and ketamine, providing needle and opioid-free procedural sedation and analgesia.</p>\n<p>Prior to Melt Pharmaceuticals, he was CEO of Keryx Biopharmaceuticals from 2015 to 2018, where he led the transformation of the organization from development stage to commercial stage focused on Auryxia, an oral product for the treatment of hyperphosphatemia and iron deficiency anemia, and ultimately leading to a merger with Akebia Therapeutics. In 2013 and 2014, he was chief commercial officer at AMAG Pharmaceuticals where he was closely involved with Feraheme, a leading intravenous product for the treatment of iron deficiency. From 2000-2012, he was at Genzyme Corp.</p>\n<p>Mr Madison will be appointed as a director of the company during June 2021 prior to which relevant Aim Rules disclosures will be made via a separate announcement.</p>\n<p>Tim Watts, Shield's current CEO, will step down as CEO on June 1, but will remain with the group as an executive director until September 30, 2021 to ensure an effective transition at which point he will also step down from the board.&nbsp;</p>\n<p>Commenting on the news, Shield chairman Hans Peter-Hasler said: \"I am delighted that Greg will be joining Shield. He brings highly relevant operating experience in growing and leading organizations, as well as deep knowledge in iron deficiency which will be invaluable as we launch and grow Accrufer in the US and extend the commercialization of Feraccru/Accrufer in other parts of the world. I welcome Greg to Shield and wish him every success. I would also like to thank Tim for his substantial contribution to Shield over the last three years, first as CFO and then as CEO since April 2020. He has played a crucial role in bringing Shield to the point at which Accrufer can be launched in the US.\"&nbsp;</p>\n<p>&nbsp;</p>", "date": "2021-05-28 12:14:00", "meta_title": "Shield Therapeutics appoints new CEO", "meta_keywords": "Shield Therapeutics, Appointment, Greg Madison, CEO, Chief executive", "meta_description": "Shield Therapeutics appoints new CEO", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-28 12:13:41", "updated": "2021-05-28 12:20:57", "access": NaN, "url": "https://www.thepharmaletter.com/article/shield-therapeutics-appoints-new-ceo", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "shieldbig.jpg", "image2id": "shieldsmall.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Hematology", "topic_tag": "Boardroom, Management", "geography_tag": "UK", "company_tag": "Shield Therapeutics", "drug_tag": "Accrufer, Feraccru", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": "Greg Madison", "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-28 12:14:00"}